Literature DB >> 16849538

Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression.

Mireia Camós1, Jordi Esteve, Pedro Jares, Dolors Colomer, María Rozman, Neus Villamor, Dolors Costa, Ana Carrió, Josep Nomdedéu, Emili Montserrat, Elías Campo.   

Abstract

Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) is an infrequent leukemia subtype with characteristic clinicobiological features. This translocation leads to fusion of MYST3 (MOZ) and CREBBP (CBP) genes, probably resulting in a disturbed transcriptional program of a myelomonocytic precursor. Nonetheless, its gene expression profile is unknown. We have analyzed the gene expression profile of 23 AML patients, including three with molecularly confirmed MYST3-CREBBP fusion gene, using oligonucleotide U133A arrays (Affymetrix). MYST3-CREBBP cases clustered together and clearly differentiated from samples with PML-RARalpha, RUNX1-RUNX1T1, and CBFbeta-MYH11 rearrangements. The relative expression of 46 genes, selected according to their differential expression in the high-density array study, was analyzed by low-density arrays in an additional series of 40 patients, which included 7 MYST3-CREBBP AML cases. Thus, genes such as prolactin (PRL) and proto-oncogene RET were confirmed to be specifically overexpressed in MYST3-CREBBP samples whereas genes such as CCND2, STAT5A, and STAT5B were differentially underexpressed in this AML category. Interestingly, MYST3-CREBBP AML exhibited a characteristic pattern of HOX expression, with up-regulation of HOXA9, HOXA10, and cofactor MEIS1 and marked down-regulation of other homeobox genes. This profile, with overexpression of FLT3, HOXA9, MEIS1, AKR7A2, CHD3, and APBA2, partially resembles that of AML with MLL rearrangement. In summary, this study shows the distinctive gene expression profile of MYST3-CREBBP AML, with overexpression of RET and PRL and a specific pattern of HOX gene expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849538     DOI: 10.1158/0008-5472.CAN-05-4601

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Accurate identification of A-to-I RNA editing in human by transcriptome sequencing.

Authors:  Jae Hoon Bahn; Jae-Hyung Lee; Gang Li; Christopher Greer; Guangdun Peng; Xinshu Xiao
Journal:  Genome Res       Date:  2011-09-29       Impact factor: 9.043

Review 2.  Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes.

Authors:  Brianna J Klein; Marie-Eve Lalonde; Jacques Côté; Xiang-Jiao Yang; Tatiana G Kutateladze
Journal:  Epigenetics       Date:  2013-10-29       Impact factor: 4.528

Review 3.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 4.  The MOZ histone acetyltransferase in epigenetic signaling and disease.

Authors:  Samuel Carlson; Karen C Glass
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

Review 5.  RBR E3-ligases at work.

Authors:  Judith J Smit; Titia K Sixma
Journal:  EMBO Rep       Date:  2014-01-27       Impact factor: 8.807

6.  β-Catenin activates the HOXA10 and CDX4 genes in myeloid progenitor cells.

Authors:  Ling Bei; Chirag Shah; Hao Wang; Weiqi Huang; Rupali Roy; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

7.  Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.

Authors:  Muzaffar Ali; Kezhi Yan; Marie-Eve Lalonde; Cindy Degerny; Scott B Rothbart; Brian D Strahl; Jacques Côté; Xiang-Jiao Yang; Tatiana G Kutateladze
Journal:  J Mol Biol       Date:  2012-10-12       Impact factor: 5.469

Review 8.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

Review 9.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

10.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.